Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Viatris's latest financial disclosures highlight a mix of positive and negative developments, resulting in mixed implications for potential investors.</li><li>In examining Viatris's performance for 2024 and their outlook for 2025, there are notable strategic strengths and ongoing challenges to consider.</li><li>In 2024, Viatris reported a modest revenue growth of 2% on a divestiture-adjusted operational basis, reaching approximately $14.7 billion, consistent with their guidance.</li></ul>

Viatris's latest financial disclosures highlight a mix of positive and negative developments, resulting in mixed implications for potential investors.In examining Viatris's performance for 2024 and their outlook for 2025, there are notable strategic strengths and ongoing challenges to consider.In 2024, Viatris reported a modest revenue growth of 2% on a divestiture-adjusted operational basis, reaching approximately $14.7 billion, consistent with their guidance.

Viatris Inc.: Expanding Footprint in China To Change The Game!

<ul><li>Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position.</li><li>Notably, the company delivered significant revenue growth, with total revenues reaching $3.8 billion, a 3% increase on an operational basis.</li><li>Additionally, Viatris achieved its sixth consecutive quarter of growth in terms of adjusted EBITDA and adjusted earnings per share (EPS).</li></ul>

Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position.Notably, the company delivered significant revenue growth, with total revenues reaching $3.8 billion, a 3% increase on an operational basis.Additionally, Viatris achieved its sixth consecutive quarter of growth in terms of adjusted EBITDA and adjusted earnings per share (EPS).

Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! - Major Drivers

<ul><li>Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue growth.</li><li>Under the leadership of CEO Scott Smith, the company, which was formed from the merging of Mylan and Upjohn, a division of Pfizer, has effectively integrated two global entities and streamlined its operations through strategic divestitures.</li><li>This strategic realignment has evidently positioned Viatris at a pivotal point for future growth, focusing strongly on expanding its innovative products alongside its stable base business.</li></ul>

Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue growth.Under the leadership of CEO Scott Smith, the company, which was formed from the merging of Mylan and Upjohn, a division of Pfizer, has effectively integrated two global entities and streamlined its operations through strategic divestitures.This strategic realignment has evidently positioned Viatris at a pivotal point for future growth, focusing strongly on expanding its innovative products alongside its stable base business.

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

<ul><li>Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals.</li><li>These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth.</li><li>Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod.</li></ul>

Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals.These include maintaining base business stability, driving new product revenue, and focusing on key strategic initiatives that spur future growth.Viatris announced its successful acquisition of Idorsia and its strategic R&D plans for the recent acquisitions – selatogrel and cenerimod.

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Large-Cap indexes (S&amp;P 500, Nasdaq 100, and DJI) remain bullish, all hitting new all-time highs last week while continuing to find short-term support at their respective 20-day MAs.</li>
<li>Mid-Caps (S&amp;P 400, Russell Mid-Cap) starting another leg higher following breakouts from 2-month consolidations. Small-caps (S&amp;P 600, Russell 2000) are likely to follow in the footsteps of large- and mid-caps.</li>
<li>Small-Cap indexes have been consolidating for 2.5 months following the historic rally from late-October to late-December 2023, a healthy sign. We expect they are gearing-up for another similar move higher.</li>
</ul>


Large-Cap indexes (S&amp;P 500, Nasdaq 100, and DJI) remain bullish, all hitting new all-time highs last week while continuing to find short-term support at their respective 20-day MAs.
Mid-Caps (S&amp;P 400, Russell Mid-Cap) starting another leg higher following breakouts from 2-month consolidations. Small-caps (S&amp;P 600, Russell 2000) are likely to follow in the footsteps of large- and mid-caps.
Small-Cap indexes have been consolidating for 2.5 months following the historic rally from late-October to late-December 2023, a healthy sign. We expect they are gearing-up for another similar move higher.


U.S. Dollar Rolling Over; Small-Caps to Follow Mid- And Large-Caps to New Highs; Buys in Cons. Disc.

United States

Viatris Inc. operates as a pharmaceutical company. The Company produces medicines for patients across broad range of major therapeutic areas spanning both noncommunicable and infectious diseases. Viatris serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Viatris (VTRS US)

Viatris Inc.: Expanding Footprint in China To Change The Game!

Viatris's latest financial disclosures highlight a mix of positive and negative developments, resulting in mixed implications for potential...

Baptista Research

Viatris Inc.: Expansion of Innovative Portfolio As A Vital Factor Driving Growth! - Major Drivers

Viatris's Q3 2024 results showcased key elements both bolstering and challenging its financial position. Notably, the company delivered...

Baptista Research

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

Viatris has delivered a solid performance in the second quarter of 2024, marking the fifth consecutive quarter of operational revenue...

Baptista Research

Viatris Inc.: Unlocking The Dry Eye Disease Market With Tyrvaya! - Major Drivers

Viatris Inc. released its Q1 2024 earnings and demonstrated consistent execution against core business fundamentals. These include maintaining...

Baptista Research

U.S. Dollar Rolling Over; Small-Caps to Follow Mid- And Large-Caps to New Highs; Buys in Cons. Disc.

U.S. Dollar $DXY Rolling Over; 10- and 30-Yr Treasury Yields Hit Major Resistance; Small-Caps to Follow Mid- and Large-Caps to New Highs $IWM $RTY...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)